| Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases C Barone, G Nuzzo, A Cassano, M Basso, G Schinzari, F Giuliante, ... British journal of cancer 97 (8), 1035-1039, 2007 | 157 | 2007 |
| Are markers of systemic inflammation good prognostic indicators in colorectal cancer? S Rossi, M Basso, A Strippoli, G Schinzari, E D'Argento, M Larocca, ... Clinical colorectal cancer 16 (4), 264-274, 2017 | 116 | 2017 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 106 | 2021 |
| Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease S Rossi, M Basso, A Strippoli, V Dadduzio, E Cerchiaro, R Barile, ... Clinical breast cancer 15 (5), 307-312, 2015 | 96 | 2015 |
| Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives MG Ferrara, V Di Noia, E D’Argento, E Vita, P Damiano, A Cannella, ... Cancers 12 (5), 1196, 2020 | 85 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 74 | 2020 |
| Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ... Clinical lung cancer 21 (6), 498-508. e2, 2020 | 67 | 2020 |
| Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer C Barone, M Basso, G Schinzari, C Pozzo, N Trigila, E D'Argento, ... Gastric cancer 10, 104-111, 2007 | 61 | 2007 |
| Lung and gut microbiota as potential hidden driver of immunotherapy efficacy in lung cancer C Carbone, G Piro, V Di Noia, E D’Argento, E Vita, MG Ferrara, S Pilotto, ... Mediators of inflammation 2019 (1), 7652014, 2019 | 52 | 2019 |
| The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥ 50% advanced non-small-cell lung cancer GL Banna, A Cortellini, DL Cortinovis, M Tiseo, J Aerts, F Barbieri, ... Esmo Open 6 (2), 100078, 2021 | 50 | 2021 |
| S100A13, a new marker of angiogenesis in human astrocytic gliomas M Landriscina, G Schinzari, G Di Leonardo, M Quirino, A Cassano, ... Journal of neuro-oncology 80, 251-259, 2006 | 49 | 2006 |
| Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ... Thoracic Cancer 12 (6), 880-889, 2021 | 44 | 2021 |
| Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies V Di Noia, A D’aveni, E D’argento, S Rossi, P Ghirardelli, L Bortolotti, ... ESMO open 6 (6), 100280, 2021 | 42 | 2021 |
| Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities MG Ferrara, A Stefani, M Simbolo, S Pilotto, M Martini, F Lococo, E Vita, ... Frontiers in Oncology 11, 650293, 2021 | 39 | 2021 |
| Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations? S Rossi, V Di Noia, L Tonetti, A Strippoli, M Basso, G Schinzari, ... Future Oncology 14 (10), 919-926, 2018 | 38 | 2018 |
| Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose … C Barone, M Landriscina, M Quirino, M Basso, C Pozzo, G Schinzari, ... British journal of cancer 96 (1), 21-28, 2007 | 37 | 2007 |
| Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors S Rossi, L Toschi, G Finocchiaro, V Di Noia, M Bonomi, E Cerchiaro, ... Clinical Lung Cancer 20 (2), 82-87, 2019 | 30 | 2019 |
| Anastrozole-related acute hepatitis with autoimmune features: a case report A Inno, M Basso, FM Vecchio, VA Marsico, E Cerchiaro, E D'Argento, ... BMC gastroenterology 11, 1-4, 2011 | 29 | 2011 |
| Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis S Rossi, E D’Argento, M Basso, A Strippoli, V Dadduzio, E Cerchiaro, ... Molecular diagnosis & therapy 20, 55-63, 2016 | 28 | 2016 |
| Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature P Sollena, M Mannino, F Tassone, MA Calegari, E D’Argento, K Peris Drugs in context 8, 2019 | 25 | 2019 |
Antonio GriecoProfessore associato, Università cattolica del sacro cuore, Facoltà di Medicina e Chirurgia A. Gemelli, Roma在 rm.unicatt.it 的电子邮件经过验证
Antonio GriecoProfessore associato, Università cattolica del sacro cuore, Facoltà di Medicina e Chirurgia A. Gemelli, Roma在 rm.unicatt.it 的电子邮件经过验证